Dermatologicals
Refine Search
Biotechnology
Colorado, USA-based biotech Enveda Biosciences, which is using AI to translate nature into new medicines, has announced an oversubscribed $130 million Series C funding round led by Kinnevik and FPV. 22 November 2024
Biotechnology
The landscape of atopic dermatitis (AD) treatment is advancing with approvals of oral and topical Janus kinase (JAK) inhibitors across the seven major pharmaceutical markets (7MM; USA, France, Germany, Italy, Spain, UK and Japan). 20 November 2024
Biotechnology
Johnson & Johnson and partner Protagonist Therapeutics have reported positive topline results from two Phase III studies testing a first-in-class oral peptide. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for Dupixent(dupilumab), Regeneron and partner Sanofi revealed late Friday. 18 November 2024
Pharmaceutical
Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for approving and overseeing therapeutic products, has granted marketing approval for Anzupgo (delgocitinib) cream. 14 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Pharmaceutical
Almirall, the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 million. 11 November 2024
Biotechnology
New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with amlitelimab, an anti-OX40 ligand antibody, significantly reduced symptoms of atopic dermatitis (AD) and was maintained even after treatment stopped. 9 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted a Rare Pediatric disease designation for BPM31510T, an investigational treatment for epidermolysis (EB) from BPGbio. 4 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2024 that beat expectations, but still saw its share price fall more than 6% to $866 in early trading. 31 October 2024
Biotechnology
Treatment with Tremfya (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, says US healthcare giant Johnson & Johnson. 25 October 2024
Biotechnology
New results show Eli Lilly Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were previously treated with Dupixent (dupilumab). 25 October 2024
Biosimilars
Iceland-based Alvotech and the US unit of Israel’s of Teva Pharmaceutical Industries today revealed that that the US Food and Drug Administration (FDA) has approved Selarsdi (ustekinumab-aekn) in a new presentation 22 October 2024
Pharmaceutical
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
The US Food and Drug Administration (FDA) has approved a 2mL pre-filled syringe and pre-filled autoinjector, each containing 320mg of Belgian drugmaker UCB’s Bimzelx (bimekizumab-bkzx), to treat psoriasis. 14 October 2024
Biosimilars
Bio-Thera Solutions and Hungary’s Gedeon Richter have reached an exclusive commercialization and license agreement. 14 October 2024
Biotechnology
Danish dermatology specialist Leo Pharma has revealed plans to cut 200 jobs, marking the company’s fourth workforce reduction since 2022. 11 October 2024
Generics
Further expanding its generic drug foot print, Swiss drug giant Novartis (NOVN: VX) is adding to its franchise with a definitive agreement to acquire Melville, New York, USA-based private equity-owned, specialty dermatology generics company Fougera Pharmaceuticals for $1.525 billion in an all-cash transaction. 3 May 2012
Pharmaceutical
Following public comment periods for both transactions, the US Federal Trade Commission has approved final orders settling charges that Canada-based Valeant Pharmaceuticals International TSX: VRX) two proposed acquisitions of dermatology businesses ' one from Sanofi and one from Johnson & Johnson (The Pharma Letters July 11 and 18, 2011) ' would have been anticompetitive and in violation of Section 7 of the Clayton Act and Section 5 of the FTC Act. 23 February 2012
Pharmaceutical
Japan's Maruho says it has acquired Cutanea Life Sciences (CLS), a privately held dermatology development company based in Villanova, Pennsylvania, USA. CLS will become a wholly-owned subsidiary of Maruho. 15 February 2012
Biotechnology
US biotech firm RegeneRx Biopharmaceuticals. (OTC Bulletin Board: RGRX) revealed yesterday that it has hired investment bankers, Ameritech Advisors and Aurora Capital to help the company evaluate and explore potential strategic opportunities. 2 February 2012
Pharmaceutical
Independent Danish drugmaker LEO Pharma says that the US Food and Drug Administration has approved its Picato (ingenol mebutate) gel (0.015%, 0.05%) as a treatment for actinic keratoses (AK) on the face, scalp, trunk and extremities. 29 January 2012
Pharmaceutical
The completion of the pneumonia data audit and confirmation of the timeline for Switzerland-based Basilea's (SIX: BSLN) European data filing of ceftobiprole brings the company a step closer to achieving a licensing deal for the drug, comment analysts at Edison Investment Research. Global sales of other broad spectrum antibiotics are in a high growth phase. 13 January 2012
Biotechnology
Privately-held Danish drugmaker LEO Pharma A/S has signed a multi-million dollar in-licensing deal with the US biotech company Virobay to develop an oral treatment for psoriasis. The in-licensing deal concerns an innovative compound which has the potential to be the first on the market with its specific mode of action. 10 January 2012
Pharmaceutical
USA-based Apricus Biosciences (Nasdaq: ARI) has signed an exclusive license agreement with Canada's Stellar Pharmaceuticals (OTCQB: SLXCF) whereby the latter gains the exclusive right to sell Apricus MycoVa product for the treatment of onychomycosis (nail fungus) in Canada, following receipt of Canadian regulatory approval for such product. MycoVa combines an existing, approved drug for nail fungus, terbinafine, with the NexACT technology that enhances the absorption of the drug through the skin. 4 January 2012
Pharmaceutical
Canada's Valeant Pharmaceuticals International (TSX: VRX) has been ordered by the USA's Federal Trade Commission to divest three drugs used to treat different skin ailments, as conditions of its $345 million acquisition of Ortho Dermatologics, from Johnson & Johnson, and $425 million buy of Sanofi's Dermik Laboratories (The Pharma Letters July 11 and 18). 14 December 2011
Pharmaceutical
UK specialty drugmaker Sinclair IS Pharma plc (AIM: SPH.L) has entered into an agreement to acquire USA-based Advanced Bio-Technologies (ABT), a dermatological products company focused on scar treatment and prevention from HealthEdge Investment Partners, and certain other shareholders for a total consideration of 21.0 million ($32.8 million). 8 December 2011
Generics
California, USA-based generic drugmaker SOHM (Pinksheets: SHMN) has announced the acquisition of business and brands of privately owned Novatrend Medicament, a manufactures pharmaceutical raw material based in Pune, India. Financial terms of the deal were not disclosed. 28 November 2011
Pharmaceutical
Global pharma behemoth Pfizer (NYSE: PFE) says it has entered into a definitive agreement to acquire California, USA-based Excaliard Pharmaceuticals, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the end of the year. 23 November 2011
Pharmaceutical
In the first year following its approval for psoriasis, nearly one-half (46%) of surveyed dermatologists in the USA expect to prescribe Pfizer's janus kinase inhibitor tofacitinib (prposed trade name Janus) to patients who have failed one biologic, says advisory firm Decision Resources. 17 November 2011
Pharmaceutical
Singapore-headquartered Invida Holdings, a leading specialty biopharmaceutical company focused on the commercialization of health care brands throughout Asia Pacific, has acquired a brand portfolio from India-based Shalaks Pharmaceuticals. Financial terms of the accord were disclosed. Upon acquisition of the product portfolio from Shalaks, Invida will market the products under the Invida brand. 14 November 2011
Pharmaceutical
The psoriasis therapeutics market is forecast to show high growth until 2018 and market research firm GlobalData estimates that the sector was worth $3.6 billion in 2010 and expects it to grow at a compound annual growth rate (CAGR) of 8.1% to reach $6.7 billion by 2018. 28 September 2011
Biotechnology
At least half of surveyed dermatologists across the EU5 (France, Germany, Italy, Spain and the UK) will likely wait until Pfizer's Janus (tofacitinib) kinase (JAK) inhibitor has accumulated favorable post-marketing safety data before they will prescribe it, according to a new study from advisory firm Decision Resources. 12 September 2011
Biotechnology
Ireland-headquartered drugmaker Shire (LSE: SHP) says that Advanced BioHealing (ABH), the USA-based regenerative medicine business bought recently for $750 million (The Pharma Letter May 18), has concluded its Phase III pivotal trial of Dermagraft in subjects with venous leg ulcers. Following preliminary analysis of the top-line results, the decision has been made not to pursue the venous leg ulcer (VLU) indication. 25 August 2011
Pharmaceutical
Nycomed US Inc has announced the appointment of Brian Markison as president and chief executive Officer and member of the Board for what will be the newly-created standalone corporation created following the closing of the 9.6 billion-euro acquisition of independent Swiss drugmaker Nycomed A/S by Japan's Takeda Pharmaceuticals (The Pharma Letter May 19). 1 August 2011
Pharmaceutical
US drugmaker Allergan (NYSE: AGN) has entered into a definitive agreement for to acquire all of the outstanding shares and assets of the privately-held dermatology company Vicept Therapeutics, aimed at expanding its offering in this therapy segment, in which Allergan's biggest products is Botox (onabotulinumtoxin A). 21 July 2011
Pharmaceutical
Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ). Valeant's shares, which were already up 86% from the start of this year, rose a further 4.6% to $55.02 in morning trading on Friday after the announcement. 18 July 2011
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze